FDA Is “Conservative” On Safety, But “Appropriately So,” Pfizer Says
Executive Summary
The ongoing discussions between FDA and Pfizer over Lyrica (pregabalin) undercut the argument that the agency is too soft on industry, Pfizer Worldwide Development President Joe Feczko suggested during a Nov. 30 analyst meeting in Groton, Conn